Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation…More of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection
REPORT RATINGS
4.8 / 5.0 (127)
Cidara Therapeutics Inc reports have an aggregate usefulness score of 4.8 based on 127 reviews.